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Abstract
Background: We sought to investigate the efficacy of serum D-dimer, fibrinogen, and CA19-9 for postoperative
monitoring and prediction of survival in patients with resectable pancreatic carcinoma (PC).
Methods: One hundred and nineteen patients with resectable PC were enrolled. Serum D-dimer, fibrinogen, and
CA19-9 values were analyzed before surgery and at the stages of relapse-free and progression disease.
Results: D-dimer, fibrinogen, and CA19-9 were significantly higher at the active stage of PC than those at the
relapse-free stage [1059.2 (1690.1) ng/ml vs 485.18 (289.84) ng/ml, (3.71 ± 0.83) g/l vs (2.75 ± 0.52) g/l, 207.2 (681.8)
U/ml vs 24.5 (30) U/ml, respectively, p < 0.01]. Patients with elevated preoperative D-dimer had significantly shorter
overall survival (18.9 ± 1.9 months vs 29.2 ± 2.6 months, p < 0.01) and progression-free survival (10.6 ± 1.2 months vs
20.4 ± 2.4 months, p < 0.01) than did those with low D-dimer. The correlation between CA19-9 values and survival
depended on the threshold value of CA19-9: when the threshold value was 37 U/ml, there was no correlation
between CA19-9 and survival; when the threshold value was 253.8 U/ml (median CA19-9 for the enrolled patients),
patients with elevated preoperative CA19-9 had significantly shorter overall survival (19.9 ± 2. 1 months vs 29.0 ± 2.
7 months) and progression-free survival (11.5 ± 1.5 months vs 21.0 ± 2. 6 months) than did the patients with low
CA19-9 (p < 0.01); when the threshold value was 1000 U/ml, the overall survival was 15.5 ± 2.3 months vs 28.0 ± 2.
0 months and the progression-free survival 8.9 ± 1.9 months vs 19.1 ± 1.9 months (p < 0.01). There was no correlation
between fibrinogen and overall survival (25.8 ± 2.1 months vs 21.2 ± 2.9 months; p = 0.096) and progression-free
survival (17.8 ± 2.1 months vs 12.7 ± 1.7 months; p = 0.168).
Conclusions: For postoperative monitoring of patients with resectable PC, D-dimer, fibrinogen, and CA19-9 may be
used as markers for monitoring disease relapse, but only preoperative D-dimer could predict survival.
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Background
Pancreatic carcinoma (PC) is a leading cause of cancer-
related mortality, with 5-year survival less than 8% [1, 2].
Despite substantial therapeutic progress, PC remains
one of the most aggressive cancers. Radical surgery is
the most effective therapy for resectable PC, but postop-
erative recurrence or metastatic disease are barriers to
prolonged survival. For most patients, the disease pro-
gresses soon after surgery, and, unfortunately, imaging is
not sufficiently sensitive to detect early recurrence or
metastasis. Thus, better markers for post-resection
disease monitoring are needed and are being investi-
gated [3–7].
Abnormalities in the coagulation/fibrinolytic system,
especially plasma D-dimer and fibrinogen, have been
identified in cancer patients. D-dimer is a degradation
product of crosslinked fibrin and a sign of fibrinolytic
hyperfunction in vivo. D-dimer has been reported to be
a marker of various cancers [8–10]. Fibrin and fibrino-
gen are identified as major components of the tumor
stroma enveloping tumor cells. Plasma D-dimer values
and fibrinogen have been reported to be prognostic fac-
tors for PC [11–13], but most of these reports focused
on metastatic PC, and the results were conflicting [12,
14]. CA 19-9, or sialyl Lewis-a (sLea), is a glycolipid and
an O-linked glycoprotein expressed on the surface of
cancer cells. CA19-9 is derived from an aberrant
pathway during production of its normal counterpart,
disialyl Lewis-a. CA19-9 is widely used as biomarker for
PC and can be combined with other markers, despite
having several limitations [3–7]. So, we investigated
whether serum D-dimer, fibrinogen, and CA19-9 are re-
liable markers for postoperative monitoring and predic-
tion of patient survival for resectable PC.
Methods
Patients
Subjects (N = 119) were included who met the following
criteria: (1) histological confirmation of the diagnosis; (2)
tumor resectability, confirmed intraoperatively and by
histopathological examinations; (3) radical surgery per-
formed; (4) plasma D-dimer, fibrinogen, and CA19-9
values were measured before surgery (samples taken
within 7 days before surgery) and regularly after surgery
(most patients were followed every 1 month in the first
year and then every 3 months but some had shorter or
longer follow-ups); (5) The subjects also had adequate
clinical information for survival analysis in patient re-
cords and death that was tumor-related (Table 1). Pa-
tients with apparent inflammatory diseases, a history of
thrombosis or treatment with drugs that might influence
the coagulation/fibrinolytic system, or severe jaundice
that might influence CA19-9 were excluded. Also, 30
samples from healthy individuals and 40 samples from
Table 1 Relationships between clinicopathological characteristics and preoperative plasma D-dimer, fibrinogen, and CA19-9 values
in 119 PC patients
Variable Total
(n)
D-dimer (ng/ml) Fibrinogen (g/l) CA19-9 (U/ml)
≤500a >500 p value ≤4a >4 p value ≤37a >37 p value
Sex 119 0.809 0.709 0.323
Male 70 37 33 48 22 15 55
Female 49 27 22 32 17 7 42
Age (years) 119 0.580 0.352 0.071
≤60 66 34 32 42 24 16 50
>60 53 30 23 38 15 6 47
Tumor size 119 0.514 0.926 0.718
≤4 cm 94 52 42 63 31 18 76
>4 cm 25 12 13 17 8 4 21
TNM 119 0.116 0.512 0.564
I 32 21 11 23 9 7 25
II 87 43 44 57 30 15 72
Lymphatic metastasis 119 0.678 0.674 0.036
Negative 95 52 43 63 32 14 81
Positive 24 12 12 17 7 8 16
Tumor differentiation 119 0.266 0.256 0.842
1–2 grade 90 51 39 63 27 17 73
3 grade 29 13 16 17 12 5 24
aNormal upper limit
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patients with serous pancreatic cystadenoma were col-
lected as controls. The “relapse-free stage” was defined
as no new lesions found by CT or MRI. “Progressive dis-
ease” was defined as new lesions found by CT or MRI or
biopsy.
Biomarker measurements
Plasma D-dimer was measured with Innovance D-dimer
immunoassays with the Vidas D-dimer kit (VIDAS DD,
France); fibrinogen was measured by immunoturbidime-
try. CA19-9 was measured with a chemiluminescent im-
munoassay. All blood samples were collected in the
early morning, fasting. Normal reference values for
plasma D-dimer, fibrinogen, and CA19-9 were 0–
500 ng/ml, 2–4.0 g/l, and 0–37 U/ml, respectively.
Statistical analysis
Measurements were reported as means ± SEM or as me-
dians (interquartile range), depending on the distribution
of data. An independent sample Student’s t test and a non-
parametric test were used to make comparisons between
groups. A Chi-squared test was used to evaluate the asso-
ciation between clinicopathological measurements and D-
dimer, fibrinogen, or CA19-9 values. Survival outcomes
were analyzed with a Kaplan-Meier method, and compari-
sons between groups were made using a log-rank test. To
establish a COX regression model analysis of independent
factors for survival of patients with PC, statistical analyses
were performed with SPSS17.0 software (p values ≤0.05
were considered statistically significant).
Results
Preoperative plasma D-dimer, fibrinogen, and CA19-9
values in PC patients
The median (interquartile range) of preoperative plasma
D-dimer and CA19-9 were 450.0 (688.3) ng/ml and 253.8
(1188) U/ml, respectively. Fibrinogen was (3.59 ± 0.84) g/l.
Plasma D-dimer values were above 500 ng/ml in 55
(46.2%) patients; 32.8% of patients had hyperfibrinogemia;
and 100 (84.0%) had higher than normal CA19-9. In
healthy controls, the median (interquartile range) of
plasma D-dimer and CA19-9 were 109.89 (124.09) ng/ml
and 12.27(10.14) U/ml, respectively, and fibrinogen was
(2.49 ± 0.37) g/l. For patients with serous pancreatic cysta-
denoma, the median (interquartile range) of plasma D-
dimer and CA19-9 were 218.86 (227.27) ng/ml and
Table 2 Plasma D-dimer, fibrinogen, and CA19-9 at various stages of PC
Serum test Relapse-free stage Progressive disease z/t p
D-dimer (ng/ml) 485.18 (289.84) 1059.2 (1690.1) −7.490 <0.001
Fibrinogen (g/l) 2.75 ± 0.52 3.71 ± 0.83 −10.228 <0.001
CA19-9 (U/ml) 24.5 (30) 207.2 (681.8) −8.669 <0.001
Eight patients were excluded because they also had deep vein thrombosis, and two were excluded for serious infections. Samples from patients considered at
relapse-free stage were extracted 1.8 months (median) before progressive. Samples from patients considered progressive disease were extracted 5 days (median)
before progressive disease
a b
Fig. 1 Kaplan-Meier curves for OS (a) and for PFS (b) for PC patients stratified by preoperative plasma D-dimer
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28.73(28.9) U/ml, respectively, and fibrinogen was (2.78 ±
0.50) g/l. Three biomarkers were higher in patients with
serous pancreatic cystadenoma than healthy controls, but
all were within the normal range. A Chi-squared test
showed that CA19-9 was a more sensitive marker for PC
than D-dimer or fibrinogen (χ2 = 37.46 and 64.36, respect-
ively, p < 0.01). There were no significant correlations be-
tween clinicopathological characteristics (sex, age, tumor
size, TNM stage, lymphatic metastasis, tumor differenti-
ation) and plasma D-dimer or fibrinogen values (p > 0.05).
However, among the subset of patients who had lymphatic
metastases, CA19-9 values were significantly higher than
in those who did not have metastases (p = 0.036).
Postoperative plasma D-dimer, fibrinogen, and CA19-9
values as biomarkers for postoperative monitoring of PC
As shown in Table 2, plasma D-dimer, fibrinogen, and
CA19-9 increased significantly when disease was pro-
gressive (p < 0.001). Sensitivities of D-dimer, fibrinogen,
and CA19-9 were 82.6, 40.4, and 79.8%, respectively.
Preoperative plasma D-dimer as a biomarker for survival
prediction
Patients were followed from 3 to 66 months postopera-
tively. Overall survival (OS) was defined as the interval
between the date of surgery and either the time of death
due to PC or the last follow-up. Progression free survival
(PFS) was defined as the interval between the date of
surgery and either the time of disease progression or the
last follow-up. Disease progression was confirmed by
imaging examination or pathological examination.
Figure 1 illustrates that patients with elevated pre-
operative D-dimer values (>500 ng/ml) had significantly
shorter OS (18.9 ± 1.9 months vs 29.2 ± 2. 6 months; p =
0.001) and PFS (10.6 ± 1. 2 months vs 20.4 ± 2.4 months;
p = 0.001) than did those with lower (≤500 ng/ml) D-
dimer. In contrast, as illustrated in Fig. 2, there was no
correlation between preoperative fibrinogen and OS
(25.8 ± 2.1 months vs 21.2 ± 2.9 months, p = 0.096), and
PFS (17.8 ± 2.1 months vs 12.7 ± 1.7 months, p = 0.168).
D-dimer was abnormally high in 48 patients, and
CA19-9 was elevated in 38 patients who were consid-
ered at relapse-free stage according to imaging. Statis-
tical analysis showed that abnormally higher D-dimer
was associated with shorter OS (19.2 ± 2.5 months vs
27.2 ± 2.4 months, p = 0.017), but there was no differ-
ence between abnormal and normal CA19-9 (21.5 ±
2.9 months vs 25.1 ± 2.3 months, p = 0.265). Elevated D-
dimer and CA19-9 values were associated with shorter
PFS (13.2 ± 2.3 months vs 17.7 ± 2.3 months and 12.4 ±
a b
Fig. 2 Kaplan-Meier curves for OS (a) and for PFS (b) for PC patients stratified by preoperative plasma fibrinogen
Table 3 Comparisons of survival and preoperative CA19-9 in PC patients
Variable CA19-9 (U/ml)
≤37 >37 ≤253.8 >253.8 ≤1000 >1000
OS (m) 27.8 ± 3.9 23.8 ± 1.8 29.0 ± 2.7 19.9 ± 2.1 28.0 ± 2.0 15.5 ± 2.3
PFS (m) 18.8 ± 2.9 15.1 ± 1.6 21.0 ± 2.6 11.5 ± 1.5 19.1 ± 1.9 8.9 ± 1.9




Fig. 3 Kaplan-Meier curves for OS and PFS for PC patients stratified by preoperative CA19-9. a, b Threshold value of 37 U/ml. c, d Threshold value
of 253.8 U/ml. e, f Threshold value of 1000 U/ml
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2.3 months vs 17.8 ± 2.3 months, p = 0.065 and 0.074, re-
spectively), but these differences were not significant.
Table 3 and Fig. 3 illustrate relationships between pre-
operative CA19-9 values and survival, and OS and PFS
depended on the CA19-9 threshold value. When the
threshold value was 37 U/ml, it did not affect the sur-
vival. If the threshold value was 253.8 or 1000 U/ml, pa-
tient survival was negatively correlated with CA19-9
values. Tables 4 and 5 show that preoperative D-dimer
was an independent risk factor for PFS for patients and
that preoperative D-dimer and CA19-9 were independ-
ent factors affecting OS.
Discussion
We investigated whether serum D-dimer, fibrinogen,
and CA19-9 are reliable biomarkers for postoperative
monitoring and prediction of survival in patients with
resectable PC. We found that plasma D-dimer values
could predict OS and PFS of PC and CA19-9 correlated
with OS and PFS but only when the threshold value
exceeded normal values and there was no correlation be-
tween fibrinogen and OS or PFS. Also, D-dimer, fibrino-
gen, and CA19-9 were significantly higher with active
disease than when the cancer is at a relapse-free stage.
D-dimer and CA19-9 were abnormally high in some pa-
tients who were considered to be at a relapse-free stage
according to CT or MRI scan. Furthermore, patients
with abnormally high D-dimer had shorter OS than
those with normal D-dimer. Likely, rising D-dimer and
CA19-9 values may predict early postoperative tumor re-
currence or progression of PC, but more work is re-
quired to confirm this.
Some studies have indicated that the coagulation/fi-
brinolytic system is activated in cancer patients and it
may contribute to cancer progression [15, 16]. Thus,
tumor-related degradation products of the coagulation
and fibrinolytic system have been proposed to predict
tumor load and prognosis [15, 16]. Plasma D-dimer is a
procoagulation factor that may reflect the presence of
micrometastases or circulating tumor cells, which may
be responsible for tumor recurrence [17]. Hyperfibrino-
genemia can enhance the sustained adherence of tumor
cell emboli in the vasculature of target organs, helping
to establish metastases [18]. Because of a likely involve-
ment of the coagulation/fibrinolytic system in cancer, we
studied whether D-dimer and fibrinogen are useful bio-
markers for postoperative monitoring and survival
prediction for resectable PC. We found that although
plasma D-dimer and fibrinogen were higher when dis-
ease was active, only D-dimer values were correlated
with OS and PFS.
Our observations on the coagulation/fibrinolytic sys-
tem in PC can be compared with other reports, although
this is difficult because of differences in clinical circum-
stances and study objectives. Stender’s group [19] re-
ported that D-dimer is prognostic for non-resectability
of PC, and Durcynski et al. [20, 21] reported that high
D-dimer values may predict unresectability even when
imaging studies predicted resectability. Liu et al. [12] in-
dicated that plasma D-dimer and platelet counts and
treatment response are independent prognostic factors
for OS which was consistent with our results. Tas’ group
[14] reported that serum D-dimer was elevated in pa-
tients with metastatic pancreatic adenocarcinoma. Sun
et al. [22] found that pretreatment plasma D-dimer
values were potentially prognostic in pancreatic adeno-
carcinoma even in the absence of venous thrombo-
embolism. Most current study objectives are focused on
unresectable or metastatic pancreatic adenocarcinoma
which differ from our objectives. Thus, D-dimer mea-
surements may have clinical utility for managing PC.
Studies of fibrinogen in PC, such as those by Qi and
colleagues [13] suggest that hyperfibrinogen with associ-
ated systemic inflammatory response was predictive of
poor prognosis in advanced PC. Wang’s group [23] re-
ported that pretreatment platelet and fibrinogen corre-
lated with tumor progression, metastases, and OS for
patients with PC. Guo’s group [11] reported that ele-
vated fibrinogen may predict metastases. Our results ap-
pear to contradict these, which may be explained by
patients at different disease stages. Thus, the status of fi-
brinogen with respect to clinical assessment of PC is
uncertain.
Serum CA19-9 has been used as a marker for diagno-
sis and therapeutic monitoring of PC, but few studies
have investigated the value of CA19-9 for predicting sur-
vival in resectable PC. We found that serum CA19-9
could not predict survival in PC when the threshold
value was set at 37 U/ml, which conflicts with the con-
clusion from Ballehaninna’s group [24], but this warrants
study because we included 19 patients with CA19-9 ≤
37 U/ml. When we analyzed survival using CA19-9
values of >1000 or 253.8 U/ml (median CA19-9 of all
subjects), the patients had significantly shorter OS and
Table 4 COX regression model analysis of PFS for PC patients
B SE Wald Sig. Exp (B)
Preoperative D-dimer 0.000 0.000 12.780 0.000 1.000
Preoperative fibrinogen 0.097 0.145 0.443 0.506 1.102
Preoperative CA19-9 0.000 0.000 2.189 0.139 1.000
Table 5 COX regression model analysis of OS for PC patients
B SE Wald Sig. Exp (B)
Preoperative D-dimer 0.000 0.000 6.250 0.012 1.000
Preoperative fibrinogen 0.185 0.162 1.298 0.255 1.203
Preoperative CA19-9 0.000 0.000 5.071 0.024 1.000
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PFS. Thus, it appears that if an appropriate threshold
value of CA19-9 is used, CA19-9 can be a predictor of
survival in resectable PC. This opinion is corroborated
by work by Qi’s group [13], who reported that CA19-9 ≥
1000 U/ml were prognostic for poor OS. Matsumoto et
al. [25] reported that preoperative CA19-9 ≥ 300 U/ml
values are independent risk factors for early recurrence
of PC. In other work in PC, early decreases in CA19-9
reportedly predicted favorable outcomes in advanced
disease [26]. In this study, we found that positive expres-
sion of CA19-9 was greater than that of D-dimer and fi-
brinogen. This finding may also reflect the fact that
activation of the coagulation/fibrinolytic system mostly
occurs in advanced disease, and most of our patients
had early-stage disease. In addition, most of our patients
had small tumors and a low rate of lymph node
metastases.
Our study is limited as are other studies to identify
cancer biomarkers. Scara’s group [27] reported that al-
though many putative biomarkers for PC have been pro-
posed, most lack validation and none has been shown to
possess the requisite sensitivity and specificity to be in-
troduced into clinical use.
Conclusions
For postoperative monitoring of patients with resect-
able PC, fibrinogen and CA19-9 may be used as
markers, but only preoperative D-dimer predicts sur-
vival. This information may be useful for the care and
counseling of patients who undergo surgery for pan-
creatic adenocarcinoma.
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